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A B S T R A C T
Increasing evidences support the notion that the impairment of intracellular degradative machinery is re-
sponsible for the accumulation of oxidized/misfolded proteins that ultimately results in the deposition of protein
aggregates. These events are key pathological aspects of “protein misfolding diseases”, including Alzheimer
disease (AD). Interestingly, Down syndrome (DS) neuropathology shares many features with AD, such as the
deposition of both amyloid plaques and neurofibrillary tangles. Studies from our group and others demonstrated,
in DS brain, the dysfunction of both proteasome and autophagy degradative systems, coupled with increased
oxidative damage. Further, we observed the aberrant increase of mTOR signaling and of its down-stream
pathways in both DS brain and in Ts65Dn mice.
Based on these findings, we support the ability of intranasal rapamycin treatment (InRapa) to restore mTOR
pathway but also to restrain oxidative stress resulting in the decreased accumulation of lipoxidized proteins. By
proteomics approach, we were able to identify specific proteins that showed decreased levels of HNE-mod-
ification after InRapa treatment compared with vehicle group. Among MS-identified proteins, we found that
reduced oxidation of arginase-1 (ARG-1) and protein phosphatase 2A (PP2A) might play a key role in reducing
brain damage associated with synaptic transmission failure and tau hyperphosphorylation. InRapa treatment, by
reducing ARG-1 protein-bound HNE levels, rescues its enzyme activity and conceivably contribute to the re-
covery of arginase-regulated functions. Further, it was shown that PP2A inhibition induces tau hyperpho-
sphorylation and spatial memory deficits. Our data suggest that InRapa was able to rescue PP2A activity as
suggested by reduced p-tau levels.
In summary, considering that mTOR pathway is a central hub of multiple intracellular signaling, we propose
that InRapa treatment is able to lower the lipoxidation-mediated damage to proteins, thus representing a va-
luable therapeutic strategy to reduce the early development of AD pathology in DS population.
1. Introduction
An increasing number of studies highlight the involvement of
aberrant mTOR signaling in the pathogenesis and progression of neu-
rodegenerative disorders, including Alzheimer Disease (AD) [1,2].
Indeed, mTOR pathway has a prominent role in the central nervous
system through the regulation of several intracellular processes, such
as, protein synthesis, transcription, autophagy, metabolism, and orga-
nelle biogenesis [3,4]. These functions are central for the maintenance
of brain homeostasis and to regulate the proliferation of neural stem
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cells, the assembly of circuits, the plasticity of synapses and behavioral
aspects like feeding, sleep and circadian rhythms [5,6]. As a con-
sequence, mTOR pathway dysfunction is implicated in different types of
brain disorders such as autism, epilepsy, Parkinson disease and AD.
Noteworthy, experimental evidences showed that aberrant mTOR sig-
naling is closely associated with the presence of the two key patholo-
gical features of AD: senile plaques, composed mainly of fibrillar β-
amyloid (Aβ) peptide, and neurofibrillary tangles (NFT), composed of
hyperphosphorylated tau protein [1,2,7–9].
Recently, we and others have investigated the role of mTOR in the
development of AD [7,9–15]; we showed that in subjects with AD and
AD-like dementia, as in Down syndrome (DS), the activation of mTOR
signaling contributes to Aβ production and tau hyperphosphorylation
[7,16,17]. DS, a genetic disorder characterized by the triplication of
chromosome 21, is the most frequent genetic cause of intellectual dis-
ability associated with neurologic deficiencies, including early onset AD
high incidence of clinical symptoms in the late 40ys of age [18–21]. The
early hyperactivation of mTOR signaling correlates with tau hyper-
phosphorylation in the brains of young DS subjects. In addition, hy-
perphosphorylation of mTOR is associated with increased activation of
PI3K/Akt axis, decreased autophagosome formation, increased oxida-
tive stress (OS) and accumulation of oxidized proteins [17,22]. Based
on these evidences, pharmacological manipulation of mTOR signaling
could represent a promising approach to reduce brain damage and so
far, has entered clinical trials for several disorders [8,23].
Published data demonstrated the neuroprotective effects of oral
administration of rapamycin in 3xTg-AD mice and J20 mouse models of
AD, as indexed by reduced accumulation of plaques and tangles and
improved cognitive function [11–13,15,24,25]. We recently proved
that administration of rapamycin by intranasal route in Ts65Dn mice
(transgenic mouse model of DS) is able to rescue aberrant mTOR sig-
naling by restoring autophagosome formation and by reducing Aβ
production and tau hyperphosphorylation [26]. These effects were as-
sociated with the amelioration of cognitive function.
Based on these findings, we extended our study to investigate if
intranasal administration of rapamycin (InRapa) was able to reduce
lipoxidation-mediated damage to proteins in the frontal cortex of
Ts65Dn mice. The age-dependent failure of degradative systems, in-
cluding autophagy and proteasome results in the accumulation of da-
maged mitochondria and oxidized proteins [16,27,28]. It is likely that
autophagy may provide protection against OS as supported by data
showing that Atg4, an essential protease that controls the lipid mod-
ification of Atg8 and autophagosome formation, is a direct target for
oxidation by hydrogen peroxide. On the other hand, it has also been
suggested that low levels of ROS provide a signal to regulate autophagic
survival and death processes [29,30]. Collectively, accumulated evi-
dence suggests that free radicals are upstream and downstream of
mTOR and numerous feedback and feed forward loops exist [31].
Considering the crosstalk between mTOR and OS, we have hy-
pothesized that pharmacological rescue of mTOR hyperactivation
might also be associated with reduced oxidative damage. Indeed,
published studies from our group showed that oxidized proteins are
significantly increased in the brain of DS subjects, prior and after de-
velopment of AD [27,32–34]. In addition, a decrease of LC3 II/I levels
ratio, an index of autophagosome formation, occurs early in DS brain
(before development of AD neuropathology) and persists in DS brain
with AD pathology, both compared to their respective age-matched
controls [17,27]. Oxidative damage targets different components of the
protein homeostasis control system such as GRP78, UCH-L1, V0-AT-
Pase, cathepsin D and GFAP that couples, in DS brain, with decreased
proteasome activity and reduced autophagosome formation [27,33].
Furthermore, a link between protein oxidative damage and aberrant
mTOR/autophagy axis induction was proven in Ts65Dn mice [16].
In the present study, we provide evidences demonstrating the ability
of InRapa treatment to restore, not only mTOR pathway, but also to
modulate OS, resulting in decreased accumulation of lipoxidized (i.e.
HNE-modified) proteins. Thus, the reduction of lipid peroxidation re-
actions has the potential to block/reduce the downstream attack, free
radical-mediated, to multiple cellular targets, thus preserving redox
homeostasis [35]. Among HNE-modified proteins, we found that re-
duced oxidation of arginase-1 (ARG-1) and protein phosphatase 2A
(PP2A) might play a key role in lowering brain damage associated with
synaptic transmission failure and tau hyperphosphorylation.
2. Materials and methods
2.1. Mouse colony
Ts65Dn (B6EiC3Sn a/A-Ts(1716)65Dn/J), a well-established mouse
model of DS, carries a reciprocal translocation that is trisomic for ap-
proximately 104 genes (56%) on Mmu16, from Mrpl39 to the distal
telomere, with homologues on HSA21. Mice were generated by re-
peatedly backcrossing Ts65Dn trisomic females with (B6EiC3SnF1/J)
F1 hybrid males. The parental generations were purchased from
Jackson Laboratories (Bar Harbour, ME, USA). These breeding pairs
produce litters containing both trisomic (Ts65Dn) and euploid off-
springs. The pups were genotyped to determine trisomy using standard
PCR, as described by Reinoldth [36]. Mice were housed in clear Plex-
iglas cages (20×22×20 cm) under standard laboratory conditions
with a temperature of 22±2 °C and 70% humidity, a 12-h light/dark
cycle and free access to food and water. Mice were sacrificed by cervical
dislocation. Trunk blood was collected from the site where the animal
was decapitated. Brain was dissected in two halves used, respectively,
for immunochemical and immunofluorescence analysis. All the ex-
periments were performed in strict compliance with the Italian National
Laws (DL 116/92), the European Communities Council Directives (86/
609/EEC). Experimental protocol was approved by Italian Ministry of
Health authorization n◦ 1183/2016-PR. All efforts were made to
minimize the number of animals used in the study and their suffering.
All samples were flash-frozen and stored at −80 °C until utilization.
2.2. In Rapa treatment
6-month old Ts65Dn and euploid (Eu) mice were administered with
intranasal rapamycin (In Rapa; Rapamune, Pfizer, New York, NY, USA)
and Vehicle (Veh; saline with 1% DMSO) for 12 weeks. Mice were di-
vided in 4 experimental groups Eu and Ts65Dn treated with vehicle or
rapamycin (n=10 per group) (Table 1). The treatment was conducted
3 times per week, with a dose of 0.1 μg/μl of rapamycin solution or
vehicle in 10 μl (1 μg/mouse) as previously reported [26]. The
Table 1
Samples characteristics and experimental uses.
Tissue Treatment Genotyping n Gender (m/f) Experimental Use
WB IF 2D electrophoresis IP
Frontal CX Vehicle Eu 10 6/4 8 4 8 8
Ts65Dn 10 5/5 8 4 8 8
InRapa Eu 10 6/4 8 4 8 8
Ts65Dn 10 6/4 8 4 8 8
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treatment was well tolerated and no change in body weight or in the
consumption of drinking water was observed. The rapamycin dose was
chosen from a dose response pilot study performed before the treat-
ment. In the dose–response treatment the animals were divided in three
groups (n=6 per group) and treated with 0.01, 0.05, 0.1 and 0.2 μg/μl
of rapamycin. Our data demonstrated that the dose of rapamycin ad-
ministered during the treatment, 0.1 μg/μl, was able to partially inhibit
mTOR (Ser2448) phosphorylation in the frontal cortex (Suppl. Fig. 1A
and B) and hippocampus [26].
2.3. Sample preparation
Brain tissues of Ts65Dn and euploid mice (n= 8 per group) after
treatment were sagittal divided in right and left hemispheres. The right
portion was used for Immunofluorescence studies and the left portion
was used for Biochemical and molecular biology studies. For Western
blot, Slot blot and proteomics analysis the frontal cortex was homo-
genized in RIPA buffer (pH 7.4) containing 50mM Tris-HCl (pH 7.4),
150mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 mM EDTA,
0,1% SDS, 1mM PMSF, 1mM NaF and 1mM Na3VO4. Brains were
homogenized by 20 strokes of a Wheaton tissue homogenizer. All the
samples homogenate was centrifuged at 14,000×g for 10min to re-
move cellular debris. The supernatant was extracted to determine the
total protein concentration by the BCA method (Pierce, Rockford, IL,
USA).
2.4. Measurement of total protein-bound 4-hydroxy-2-trans-nonenal (HNE-
bound protein) and 3-nitrotyrosine (3-NT)
For the analysis of HNE-bound and 3-nitrotyrosine (3- NT) protein
levels, 5 μl of the total protein extract from the frontal cortex of our
groups of treatment were incubated with 5 μl of Laemmli buffer con-
taining 0.125M Tris base pH 6.8, 4% (v/v) SDS, and 20% (v/v) gly-
cerol. The resulting samples (250 ng for each well) were loaded in each
well on a nitrocellulose membrane under vacuum using a slot blot ap-
paratus. The membranes were blocked in blocking buffer (3% bovine
serum albumin) in TBS containing 0.01% Tween 20 for 1 h at room
temperature and incubated with HNE polyclonal antibody (1:2000,
Novus Biologicals, Abingdon, UK, #NB100-63093) or an anti-3-NT
polyclonal antibody (1:1000, Santa Cruz, CA, USA, #sc-32757) in BSA
3% in TBS-T for 120min. The membranes were washed in PBS fol-
lowing primary antibody incubation three times at intervals of 5min
each. The membranes were incubated respectively with an anti-goat
and anti-mouse IgG alkaline phosphatase secondary antibody (1:5000,
Sigma–Aldrich, St Louis, MO, USA) for 1 h. The membranes were wa-
shed three times in PBS for 5min each and developed with Sigma fast
tablets (5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium
substrate [BCIP/NBT substrate]). Blots were dried, acquired with
Chemi-Doc MP (Bio-Rad, Hercules, CA, USA) and analyzed using Image
Lab software (Bio-Rad, Hercules, CA, USA). No non-specific binding of
antibody to the membrane was observed.
2.5. Two-dimensional (2D) electrophoresis
Frontal cortex homogenate from Eu (Veh and InRapa) and Ts65Dn
(Veh and InRapa) (100 μg of proteins) were precipitated in cold abso-
lute ethanol overnight. Each sample was than centrifuged at 10 000 g
for 5min. The pellet was dissolved in 200 μL of rehydration buffer: 8M
Urea, 20mM Dithiothreitol, 2% (w/v) Chaps, 0,2% Bio-Lyte, 2M
Thiourea, and Bromophenol Blue. For the first-dimension electrophor-
esis, approximately 200 μl of sample were applied to 110-mm pH 3–10
IPG® ReadyStrip (Bio-Rad, Hercules, CA, USA). The strips were then
actively rehydrated in the protean isoelectric focusing (IEF) cell (Bio-
Rad, Hercules, CA, USA) at 50 V for 18 h. The isoelectric focusing was
performed in increasing voltages as follows; 300 V for 1 h, then linear
gradient to 8000 V for 5 h and finally 20,000 V/h. Strips were then
stored at −80 °C until the 2D electrophoresis was to be performed. For
the second dimension, the IPG® Strips, were thawed and equilibrated for
10min in 50mM Tris–HCl (pH 6.8) containing 6M urea, 1% (w/v)
sodium dodecyl sulfate (SDS), 30% (v/v) glycerol, and 0.5% dithio-
threitol, and then re-equilibrated for 15min in the same buffer con-
taining 4.5% iodacetamide instead of dithiothreitol. Linear gradient
precast criterion Bis-Tris gels (12%) (Bio-Rad, Hercules, CA, USA) were
used to perform second dimension electrophoresis. Precision Protein™
Standards (Bio-Rad, Hercules, CA, USA) were run along with the sam-
ples at 200 V for 50min. After running, the gels were incubated in
fixing solution (10% acetic acid, 40% methanol) for 40min and stained
overnight at room temperature with 50mL SYPRO Ruby gel stain (Bio-
Rad, Hercules, CA, USA). The SYPRO ruby gel stain was then removed
and gels stored in deionized water. For 2D blots, gels were blotted on
nitrocellulose membranes (Bio-Rad, Hercules, CA, USA) and HNE pro-
teins were detected on the membranes. Briefly, membranes were
blocked for 1 h with 3% albumin in T-TBS, incubated with HNE poly-
clonal antibody (1:2000, Novus Biologicals, Abingdon, United
Kingdom, #NB100-63093) overnight at 4 °C. After washing with T-TBS
three times for 10min, membranes were further incubated at room
temperature for 1 h with the secondary antibody alkaline phosphatase
conjugated anti-mouse IgG (1:5000; Sigma-Aldrich, St Louis, MO, USA).
Membranes were then washed with T-TBS three times and developed
using 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium so-
lution (BCIP/NBT). In addition, we tested the specificity of anti-HNE
antibody used in the proteomic approach. Thus, 1.0 mg of protein (BSA)
was treated with 0, 1, 3 and 6mM HNE (Cayman Chemical, Ann Arbor,
MI, US) in 1ml of sodium phosphate buffer and the samples were in-
cubated in a 37 °C water bath for 2 h. The BSA-protein samples were
loaded in SDS-page and transferred to nitrocellulose membrane, which
was imaged using the Stain-Free Blot settings (Total Load) by the
ChemiDoc MP imaging system. After transfer, the blot was incubated
with HNE polyclonal antibody (1:2000) and developed using the
Chemiluminescence settings in the Chemi Doc MP imaging system.
2.6. Western blot
Western blots were performed as previously described in Ref. [26].
Briefly proteins were separated via SDS-PAGE, transferred to ni-
trocellulose membrane. After transfer, the blot was imaged using the
ChemiDoc MP imaging system using the Stain-Free Blot settings. This
total protein signal was used for total protein normalization. Than the
membrane was blocked with 3% of bovine serum albumin (SERVA
Electrophoresis GmbH, Heidelberg, Germany) and incubated over night
at 4 °C with primary antibody against: mTOR pSer2448 1:500 (Bio-Rad
Laboratories, Hercules, CA, USA #AHP2657), mTOR 1:1000 (Cell Sig-
naling, Danvers, MA, USA #2983S), Tau pSer404 1:2000 (Abcam,
Cambridge, UK #ab92676), total tau 1:1000 (Santa Cruz, Santa Cruz
CA, USA, #sc-5587), Atg12 (C-6) 1:500 (Santa Cruz, Santa Cruz CA,
USA, #sc-271688), APG5 (C-1) 1:500 (Santa Cruz, Santa Cruz CA, USA,
#sc-133158); Amyloid Precursor Protein 1:5000 (Sigma-Aldrich, St
Louis, MO, USA # A8717); LC3 1:1000 (MBL International Corporation,
Woburn, MA, USA #M152-3); PP2A 1:2000 (Genetex # GTX106334,
Irvine, CA,USA); Arginase-1 1:2000 (Genetex # GTX109242, Irvine,
CA,USA). All the membranes were incubated for 1 h at room tempera-
ture with secondary antibody horseradish peroxidase-conjugated anti-
rabbit, anti-mouse or anti-goat IgG (1:20000, Bio-Rad Laboratories,
Hercules, CA, USA). The blot was then imaged via the Chemi Doc MP
imaging system using the Chemiluminescence settings. Subsequent
determination of relative abundance via total protein normalization
was calculated using Image Lab 6.0 software (Bio-Rad Laboratories,
Hercules, CA, USA).
2.7. Image analysis
SYPRO ruby-stained gel and Blot images were obtained using a
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Chemidoc MP System (Bio-Rad, Hercules, CA, USA). All the images
were saved in TIFF format. 2D gels and 2D blots images (8 gels and 8
blots for each group of study) were analyzed by PD-Quest 2D Analysis
(7.2.0 version; Bio-Rad, Hercules, CA, USA). PD-Quest spot-detection
software allows the comparison of 2D gels as well as 2D blots, from Eu
(Veh and InRapa) and Ts65Dn (Veh and InRapa). Briefly, a master gel
was selected followed by normalization of all gels and blots according
to the total spot density. Gel-to-blot analysis was then initiated in two
parts. First, manual matching of common spots was performed, that
could be visualized among the differential 2D gels and 2D blots. After
obtaining a significant number of spots the automated matching of all
spots was then initiated. Automated matching is based on user-defined
parameters for spot detection. These parameters are based on the
faintest spot, the largest spot, and the largest spot cluster that occur in
the master gel and are defined by the user. This process generates a
large pool of data, approximately 400–800 spots. Only proteins
showing computer-determined significant differential levels between
the groups being analyzed were considered for identification. To de-
termine significant differential levels of proteins, analysis sets were
created using the analysis set manger software incorporated into the
PD-Quest software. The numbers of pixels that occur in a protein spot
were computed by the software corresponding to an increase/decrease
in protein level. The image analysis was conducted first on blot and
then on Sypro Ruby-stained expression gels. The two analyses were
compared by software to normalize HNE-modified protein value to
expression value for each spot matched.
2.8. In-gel trypsin digestion/peptide extraction
Protein spots identifies as significantly altered from our group
comparison were excised from 2D-gels and transferred to individual
Eppendorf microcentrifuge tubes for trypsin digestion as described
previously [37]. In brief, DTT and IA were used to break, and cap
disulfide bonds and the gel plug was incubated overnight at 37 °C with
shaking in modified trypsin solution. Tryptic peptide solutions were
reconstituted in water and stored at −80 °C until MS/MS analysis.
2.9. RP-HPLC-high resolution MS/MS characterization of tryptic peptides
High-resolution HPLC-ESI-MS/MS experiments were carried out by
an Ultimate 3000 RSLC nano system coupled to an LTQ Orbitrap ELITE
apparatus (Thermo Fisher Scientific, Waltham, MA, USA). Zorbax 300
SB-C18 (3.5 μm particle diameter; column dimension 1mm×150mm)
(Agilent Technologies, Santa Clara, CA, USA) was used as chromato-
graphic column. The following eluents were used: (A) 0.1% (v/v)
aqueous FA and (B) 0.1% (v/v) FA in ACN/water 80/20 v/v. The ap-
plied gradient was: 0–2min 5% B, 2–40min from 5 to 70% B (linear),
40–45min from 70 to 99% B (linear), at a flow rate of 50 μl/min with a
total run of 65min. MS spectra were collected with 120,000 resolution
and m/z range from 350 to 2000. In data-dependent acquisition mode
the five most intense multiply-charged ions were selected and frag-
mented in ion trap by using CID 35% normalized collision energy.
Tuning parameters were: capillary temperature 300 °C, source voltage
4.0 kV.
2.10. Immunofluorescence
Right brain hemispheres were removed and immersed in 4% par-
aformaldehyde for 24 h at 4 °C. Fixed brains were cryoprotected in
successive 48 h with a solution of 20% sucrose and 0.02% NaN3 at 4 °C.
Brains were frozen on a temperature-controlled freezing stage, coronal
sectioned (20 μm) on a sliding cryostat (Leica Biosystems, Wetzlar,
Germany), and stored in a solution of PBS containing 0.02% NaN3 at
4 °C. Brain sections were mounted on glass slide. Once dried, sections
were blocked with a solution containing 10% normal goat serum,
0.02% NaN3, and 0.2% Triton X-100 in TBS. Slides were then incubated
overnight at 4 °C with following antibodies: mTOR p-Ser2448 (mouse
1:500, #sc-293133 Santa Cruz, Santa Cruz CA, USA); Tau p-Ser404
(rabbit 1:500, #ab92676Abcam, Cambridge, UK). Slides were then
washed with TBS and then incubated with Alexa Fluor 488 nm and-
594nm secondary antibodies (Invitrogen Corporation, Carlsbad, CA,
USA) at 1:1500 for 2h at room temperature. Slides were then washed
again and incubated with DAPI (1:10.000). One slide per group was
stained omitting primary antibodies to establish nonspecific back-
ground signal. Cover slips were placed using a drop of Fluorimount
(Sigma-Aldrich, St Louis, MO, USA). All slides were imaged using Zeiss
AXio (Carl Zeiss, Oberkochen, Germany). All immunolabeling acquisi-
tion intensities, field sizes, and microscopy settings were kept consistent
across all images. Images were analyzed using ImageJ. Image montages
for Figures were collated in Illustrator and Photoshop Cs6 (Adobe
System, San Josè, CA, USA) software programs and were based upon
cells that most closely approximated the group means.
2.11. Immunoprecipitation
Immunoprecipitation experiments were performed using
SureBeads™ Protein A/G Magnetic Beads (BioRad SureBeads™ Protein G
#161-4023). Briefly, 100 μl SureBeads were magnetized and washed
with a solution of PBS/Tween20 0.1% v/v., then incubated for 30min
with 2 μg anti- PP2A (Genetex # GTX106334, Irvine, CA, USA) and
Arginase-1 (Genetex # GTX109242, Irvine, CA, USA) at room tem-
perature. After incubation, beads were washed 3 times with PBS/
Tween20 0.1% v/v and the beads/antibody complexes were recovered
and incubated with 100 μg of protein extracts for 1 h at room tem-
perature. Proteins were separated by SDS-PAGE followed by im-
munoblotting on a nitrocellulose membrane (Bio-Rad, Hercules CA,
USA). Membrane were incubated with the antibodies anti-HNE (1:2000,
Novus Biologicals, Abingdon, UK), and then detected by the peroxidase-
conjugated secondary antibody (1:20.000, Bio-Rad, Hercules, CA, USA)
with Clarity™ Western ECL Blotting Substrates (Bio-Rad, Hercules, CA,
US). Membranes were then acquired with ChemiDoc MP image system
(Bio-Rad, Hercules, CA, USA) and analyzed using Image Lab software
(Bio-Rad, Hercules, CA, USA).
2.12. ARG-1 activity
ARG-1 activity was measured by using the Arginase Activity Assay
Kit (Sigma-Aldrich, St. Louis, Missouri, USA) according to the manu-
facturer instructions. Arginase activity was measured in the frontal
cortex homogenate from Eu (Veh and InRapa) and Ts65Dn (Veh and
InRapa). In details 50 μg of sample were incubated in a 96 well plate
with 10 μL of Substrate buffer (L-Arginine and Mn solution) for 37 C for
2h. The reaction was stopped by adding 200 μl of the prepared Urea
reagent to each well. The samples were analyzed with a spectro-
photometer at 540 nm. The Arginase activity of our sample was de-
termined by the following equation: Activity = (A430) sample – (A430)
blank × (1mM × 50 x 103)/(A430) standard – (A430) water (V × T).
(T=Reaction time in minutes; V= sample volume (μL) added to
well (1–40 μl); 1 mM=concentration of Urea Standard; 50= reaction
volume (μL); 103=mM to μM conversion factor).
2.13. Statistical analysis
Each immunoblot experiment was performed three times using 8
samples per group. Immunohistochemistry analyzes were performed
using at least 10 sections per brain of 4 mice per group. Details on
sample size are summarized in Table 1. All statistical analyses were
performed using a non-parametric one-way ANOVA with post hoc
Bonferroni t-test. Data are expressed as mean± SD per group. All sta-
tistical analyses were performed using Graph Pad Prism 7.0 software
(GraphPad, La Jolla, CA, USA).
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3. Results
3.1. InRapa effects on mTOR/autophagy axis, AD hallmarks and protein
oxidative damage
In order to evaluate the biochemical effects of InRapa treatment in
the frontal cortex of Ts65Dn mice, we first analyzed the main target of
rapamycin, mTOR. Collected data demonstrated that Ts65Dn mice
compared with Eu Veh group show increased mTOR hyperpho-
sphorylation at Ser2448, leading to mTORC1 over activation (63.1%
increase; p=0.014; Fig. 1A and B). The administration of InRapa in
Ts65Dn mice was able to partially inhibit mTOR phosphorylation at
Ser2448 leading to the restoration of mTORC1 to physiological levels,
as demonstrated by the comparison with Eu mice. Indeed, as previously
observed in the hippocampus [26], we found in the frontal cortex of
Ts65Dn mice after InRapa treatment a significant reduction of mTOR
phosphorylation compared to Veh (49.7% decrease; p=0.027; Fig. 1A
and B). These results were validated staining of mTOR, by immuno-
fluorescence, in brain slices of mice cortex (Fig. 2A1-8). mTOR also
plays a crucial role in regulating autophagy. Our published studies
demonstrated an impairment of autophagy in the brain of Ts65Dn mice
at different ages, and the ability of rapamycin to restore autophagy by
dampening mTOR hyperactivation in the hippocampus of Ts65Dn mice
[26]. To support these results, we measured by WB the levels of LC3 II,
Atg7 and of the Atg12/Atg5 complex, which are well-recognized mar-
kers of autophagy induction, in mice in frontal cortex. Our results show
that mTORC1 over activation in Ts65Dn Veh mice leads to decreased
LC3II (about 30% reduction, p=0.01; Fig. 1A and C), Atg7 (35% re-
duction, p=0.01; Fig. 1A and F) and Atg12/Atg5 complex (25% re-
duction, p= 0.0024; Fig. 1A and G), while InRapa treatment by in-
hibiting mTOR phosphorylation led to the increase of LC3 II levels
(about 40% increase compared to Ts65Dn Veh, p=0.039; Fig. 1A and
C) and show a trend of increase for Atg7 and Atg12/Atg5 complex
(p= 0.1 and 0.052 respectively; Fig. 1A, F and G), therefore suggesting
Fig. 1. InRapa lowers tau hyper-phosphorylation and APP levels through mTOR inhibition and increased LC3 II levels. (A) Representative WB showing p-mTOR (Ser
2448), mTOR, LC3 II Atg 12, 7 and 5, p-tau (Ser404), tau, and APP total levels (B). Quantification of panel A showing mTOR protein levels, p mTOR (Ser2448)/mTOR
ratio. (C) Quantification of panel A showing LC3 II protein levels. (D) Quantification of panel A showing Tau protein levels and Tau (Ser404)/Tau ratio. (E)
Quantification of panel A showing APP protein levels. (F) Quantification of panel A showing At7 protein levels. (G) Quantification of panel A showing Atg12/Atg5
complex levels. Densitometry values shown in the bar graph are the mean of 8 (WB) samples per each group normalized per total load and are given as percentage of
Eu Veh, set as 100%. Statistical significance was determined using one–way ANOVA and Student t-test analysis (*p < 0.05, **p < 0.01, ***p < 0.001).
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Fig. 2. IF image showing mTOR and Tau expression after In Rapa treatment. Panel A: Representative immunofluorescent images showing mTOR (Ser2448) signal in
the CX of euploid treated with Veh (1,2) and InRapa (5,6) and Ts65Dn treated with Veh (3,4) and InRapa (7,8). Panel B: Representative immunofluorescent images
showing Tau (Ser404) signal in the CX of euploid treated with Veh (1,2) and InRapa and (5,6) and Ts65Dn treated with Veh (3,4) and InRapa (7,8). DAPI (blue) was
used to identify cell nuclei. Scale bar represent 100 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of
this article.)
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the increased induction of autophagy.
As reported before the restoration of autophagy by rapamycin
treatment ameliorates the aberrant regulation of APP and tau [26]. The
overexpression of APP in DS was shown in humans and mouse samples
and is confirmed in Ts65Dn Veh compared to Eu Veh, with an increase
of about 70% (p=0.0009; Fig. 1A and E). Interestingly, InRapa ad-
ministration in Ts65Dn mice (Ts65Dn InRapa) is able to reduce total
APP levels to euploid condition (about 50% decrease; p=0.0001;
Fig. 1A and E). To further investigate the efficacy of InRapa to reduce
AD-related pathological features, we also examined tau hyperpho-
sphorylation by WB (Fig. 1A) and immunofluorescence (Fig. 2B1-8)
staining. Ts65Dn mice show increased phosphorylation of tau on
Ser404 (about 162% increase, p=0.008; Fig. 1A and D) compared with
Eu mice. InRapa treatment on Ts65Dn mice demonstrated a robust
decrease of tau phosphorylation, in Ser404, when compared to Veh
Ts65Dn group (about 130% decrease, p=0.022; Fig. 1A and D). A si-
milar trend is observed in the IF images (Fig. 2B1-8).
Previous studies by our group and others demonstrated that, in DS
brain, alteration of autophagy is associated with increased OS
[16,27,33,38,39]. We evaluated the levels of two different protein
oxidation markers, 4-hydroxy-2-nonenal (HNE) protein adducts and
protein-bound 3-nitrotyrosine (3-NT) in the frontal cortex of Ts65Dn
and Eu mice treated with rapamycin or Vehicle. The increase of total 3-
NT levels is not significant in Ts65Dn mice compared with Eu mice
treated with Veh. However, InRapa treatment is able to reduce sig-
nificantly the 3-NT total levels of about 30% (p=0.045) in Ts65Dn
(Fig. 3A). A significant increase of HNE adducts was observed (about
25%, p=0.03) between Eu Veh and Ts65Dn Veh, which was is sig-
nificantly reduced by the treatment with rapamycin (40%, p=0.025,
Fig. 3B).
3.2. Proteomics profile of HNE-modified proteins
Based on the analysis of total protein oxidation levels, we further
analyzed protein-bound HNE profile by proteomics approach, in order
to identify specific proteins showing increased levels of HNE-mod-
ification.
Subsequently, cortex homogenates were separated on two-dimen-
sional (2D) gels and HNE modified-proteins were detected by im-
munoblotting (Fig. 4A). The overall intensities of protein spots that
immunoreacted with HNE antibody appeared higher in Ts65Dn Veh
group compared to Eu Veh and RAPA groups (Fig. 4B). On the other
hand, the intensity of HNE-modified proteins is reduced in Ts65Dn
treated with rapamycin compared with Ts65Dn Veh group (Fig. 4B),
confirming a reduction of HNE adducts achieved by InRapa treatment.
The 2D proteomics analyses identified a number of HNE-modified
proteins (normalized to expression levels) in the cortex of the four
groups of samples (Eu Veh, Ts65Dn Veh, Eu RAPA and Ts65Dn RAPA)
and the following results were obtained (Table 2):
• Increased HNE-bound protein levels in Ts65Dn mice compared
with Eu (Ts65Dn Vehicle/Euploid Vehicle). To evaluate the geno-
type-dependent effect, we compared the Ts65Dn mice with Eu mice
both treated with vehicle. Proteins showing increased levels of HNE-
modification were identified as: Fructose-bisphosphate aldolase A
with 12.6-fold increase; Succinyl-CoA:3-ketoacid coenzyme A
transferase 1 and Guanine deaminase with 1.3-fold increase;
Echinoderm microtubule-associated protein-like 5 with 1.6-fold in-
crease; ARG-1 with 3.0-fold increase; α-internexin with 8.9-fold
increase; 28S ribosomal protein S35 with 3.4-fold increase; Histone
H4 with 1.9-fold increase; Ubiquitin thioesterase (OTUB1) with 1.8-
fold increase; Dynein heavy chain 3 with 5.3-fold increase; Serine/
threonine-protein phosphatase 2A (PP2A) regulatory subunit α
isoform with 2.4-fold increase (Table 2). These data confirm the
increase of OS in the frontal cortex of Ts65Dn mice compared with
euploids, as displayed in the first column of the heat map (Fig. 5,
panel A), and are noticeable comparing the first and the second
column of the heat map (Fig. 5, panel B).• InRapa treatment reduces the levels of HNE-bound proteins in
Ts65Dn mice (Ts65Dn Vehicle/Ts65Dn InRapa). To investigate the
effects of rapamycin on Ts65Dn mice, we compared mice treated by
InRapa with Tg mice treated with vehicle. Proteins that showed
decreased HNE levels after InRapa treatment were identified as:
oxysterol-binding protein-related protein 1-8 with 3-fold increase,
formin-like protein 2 with 2-fold increase, endosomal/lysomomal
potassium channel with 6.6-fold increase, crescerin-2 with 20-fold
increase, ARG-1 with 3.3-fold increase and PP2A with 9.1-fold in-
crease (Table 2). Intriguingly, ARG-1 and PP2A were also identified
as HNE-modified in the comparison between Ts65Dn Veh and Eu
Veh supporting that their oxidation is a common feature of Ts65Dn
neurodegenerative process, while rapamycin is able to revert their
oxidation and most-likely recover their function. Overall the ana-
lysis of this group of comparison confirm, as previously stated, that
rapamycin is able to reduce OS levels in the frontal cortex of DS
mice. These results are displayed in the second column of the heat
map (Fig. 5, panel A) and are noticeable comparing the second and
the third column of the heat map (Fig. 5, panel B).• InRapa treatment reduces lipoxidized proteins, to levels com-
parable with Eu mice (Ts65Dn InRapa/Euploid Vehicle). In this
group of comparison, we found the increased HNE-modification of
only three proteins in Ts65Dn InRapa compared with Eu Veh. Two
proteins are in common with the first group of comparison: dynein
heavy chain 3 (3.9-fold increase) and guanine deaminase (1.3-fold
increase); while one protein, the Acyl-CoA dehydrogenase family
member 9, is newly identified as increasingly HNE-modified (3.9-
fold increase). Interestingly, these data suggest that InRapa is able to
revert the oxidation of the majority of the proteins (see comparison
Ts65Dn Veh and Eu Veh) with the exception of two, dynein heavy
chain 3 (3.9-fold increase) and guanine deaminase (Table 2). Taken
together, these findings indicate the efficacy of InRapa to sig-
nificantly reduce the levels of HNE-modifications in the frontal
cortex of Ts65Dn, although in the presence of only few oxidized
proteins compared with Eu mice. Indeed, the third column of the
heat map (Fig. 5, panel A) indicates few oxidized proteins in the
comparison between Ts65Dn InRapa and euploids, as is also no-
ticeable by observing the first and the third column of the heat map
Fig. 3. InRapa reduces protein oxidative damage. In panel A) are shown the
total protein-bound 3-NT and B) HNE of Ts65Dn mice and Eu treated with Veh
and InRapa analyzed by slot blot assay. Densitometry values shown in the bar
graph are the mean of 8 samples per each group normalized per total load and
are given as percentage of Eu Veh, set as 100%. Statistical significance was
determined using one–way ANOVA and Student t-test analysis (*p < 0.05,
*p < 0.01).
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(Fig. 5, panel B).
3.3. Validation experiments: ARG-1 and PP2A
In light of these findings, ARG-1 and PP2A were selected for vali-
dation of the proteomics results. These proteins were im-
munoprecipitated and then probed by specific HNE antibody
(Fig. 6A–D). In addition, the expression levels of PP2A and the ex-
pression levels and activity of ARG-1 were evaluated respectively by
WB and enzyme assay (Fig. 7A–C). Proteomic data show that PP2A is
significantly HNE-modified in Ts65Dn Veh group compared to Eu mice,
suggesting the reduction of its phosphatase activity. Interestingly, ra-
pamycin treatment is able to reduce the levels of HNE modifications on
PP2A in Ts65Dn mice. The results obtained by immunoprecipitating
PP2A protein confirmed proteomic data (Fig. 6A and B). Indeed, HNE-
modifications is increased (about 40% increase, p=0.04) on im-
munoprecipitated PP2A in Ts65Dn Veh group compared to Eu mice
(Fig. 6A). Conversely, InRapa treatment was able to reduce the HNE
modifications on PP2A (70% decrease, p=0.001) in Ts65Dn RAPA
compared with Ts65Dn Veh group (Fig. 6B). The analysis of PP2A ex-
pression levels show a significant increase, about 60% (p=0.05), in
InRapa Ts65Dn treated compared to Ts65Dn Veh (Fig. 7A and B).
Therefore, these data demonstrate that InRapa treatment is able to re-
cover PP2A status and conceivably its function by both decreasing HNE-
adduct levels and increasing its expression levels.
The proteomic results demonstrate the increased HNE-modification
of ARG-1 in Ts65Dn mice treated with Vehicle compared to euploid
mice, suggesting an impairment of ARG-1 activity. On the other hand,
the same protein was less HNE-modified in InRapa Ts65Dn compared
with Ts65Dn Veh group, thus suggesting the ability of rapamycin
treatment to restore its activity. To confirm our hypothesis, we first
immunoprecipitated ARG-1 and we evaluated its HNE-modification
(Fig. 6C and D). The data obtained confirm the proteomics analysis
showing an increase in HNE-modification on ARG-1 (20% increase,
p=0.01) in Ts65Dn Veh compared to Eu Veh (Fig. 6C). Interestingly,
rapamycin treatment reduces the levels of HNE-modification on ARG-1
Fig. 4. Representative 2D gel and 2D-HNE blots from Ts65Dn mice and Eu treated with Veh and InRapa. Representative 2D gel and HNE blots from Ts65Dn mice and
Eu treated with Veh and InRapa. The spots showing significantly HNE difference between the group of treatment are labeled. The spots numbers indicated on the
maps are the same as those listed in Table 2.
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(20% decrease, p=0.001) in Ts65Dn InRapa mice compared to Ts65Dn
untreated mice (Fig. 6D). In addition, we measured the expression le-
vels and the activity of ARG-1, by enzymatic assay, in the frontal cortex
of the four groups of animals used in the present study. ARG-1 ex-
pression levels showed no differences between the groups of compar-
ison (data not shown). However, in line with proteomics data, the ARG-
1 activity (Fig. 7C) is reduced in Ts65Dn Veh group compared with
euploid Veh (about 40% reduction, p=0.05). However, InRapa treat-
ment is able to recover the ARG-1 enzyme activity in Ts65Dn mice by a
45% increase (p=0.04) compared to Veh group.
4. Discussion
Several studies demonstrated the involvement of OS in DS-related
accelerated senescence and neuropathology [7,32,34,39]. Results from
our group and from others have demonstrated that OS is an early event
in the onset of pathological DS phenotype. It is supposed that the in-
crease of OS during fetal stage can modify brain development [34,40],
Table 2
Protein identified by MS/MS with significant different HNE-bound organized by groups of comparison. For each protein, full name and acronym, UNIPROT number,
fold change between groups, sequence coverage and number of identified peptides are reported.
Spot N. Protein Uniprot N. Fold Coverage Peptides
Ts65Dn Veh/Eu veh
1 Fructose-bisphosphate aldolase A (Aldo-A) P05064 12.6 14.3 5
3 Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial (SCOT-1) Q9D0K2 1.3 2.7 1
6 Echinoderm microtubule-associated protein-like 5 (EMAP-5) Q8BQM8 1.6 0.3 1
7 Arginase-1 (Arg-1) Q61176 3.0 5.2 1
8 Guanine deaminase (GAH) Q9R111 1,3 13,5 6
11 Alpha-internexin (Alpha Inx) P46660 8.9 5.4 2
12 28S ribosomal protein S35, mitochondrial (MRP-S35) Q8BJZ4 3.4 4.3 1
13 Histone H4 P62806 1.9 9.7 1
14 Ubiquitin thioesterase (OTUB1) Q7TQI3 1.8 8.9 2
15 Dynein heavy chain 3, axonemal Q8BW94 5.3 1.25 4
16 Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform (PP2A) Q76MZ3 2.4 5.43 3
Ts65Dn Veh/Ts65Dn InRapa
4 Oxysterol-binding protein-related protein 1-8 (ORP-1-8) Q91XL9 3.0 0.85 1
B9EJ86 0.8
5 Formin-like protein 2 (Flp-2) A2APV2 2.0 1.1 1
7 Arginase-1 Q61176 3.3 5.2 1
9 Endosomal/lysomomal potassium channel (TMEM175) Q9CXY1 6.6 1.6 1
10 Crescerin-2 Q3TYG6 20 2.7 3
16 Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform (PP2A) Q76MZ3 9.1 5.43 3
Ts65Dn InRapa/Eu veh
2 Acyl-CoA dehydrogenase family member 9, mitochondrial (ACAD-9) Q8JZN5 3.9 4.0 2
8 Guanine deaminase (GAH) Q9R111 1.3 13.5 6
15 Dynein heavy chain 3, axonemal Q8BW94 2.3 1.25 4
Fig. 5. Heat maps of protein-bound HNE levels.
Panel A: Heat map showing, for all the proteins
identified, the protein-bound HNE ratio between the
groups of comparison. The gray square indicates no
significant changes. Panel B: Heat maps showing, for
all the proteins identified, the protein-bound HNE
levels value, normalized on Eu Veh set as 100%, for
each of the experimental group. Proteins acronyms
are explained in Table 2 and in the list of abbrevia-
tions.
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while in later life stages is mainly involved into the neurodegenerative
phenomena contributing to the development of AD in DS patients
[7,20,21]. Interestingly, the cause of increased OS lies on genes tripli-
cated on Chr21 that are involved, directly or indirectly, in the over-
production of ROS and, in turn, in enhanced oxidative damage to
proteins, nucleic acid and lipids [19,38,41].
Among triplicated genes, one of the most relevant OS inducer is the
copper-zinc superoxide dismutase (SOD1), which when overexpressed
demonstrates an imbalance in the ratio with CAT and GPX, resulting in
the accumulation of H2O2. Among other proteins, encoded on Chr21,
that are responsible for increased OS we can further mention APP,
carbonyl reductase (CR), S100B and BACH1 [42].
Further, low levels of reducing agents and antioxidant enzymes,
together with the impairment of the proteostasis network, contribute to
exacerbation of brain pathology in DS [31]. mTOR is deeply involved in
the regulation of the proteostasis network, through the on/off switch of
translation and autophagy [4]. Autophagy is essential for preserving
cellular homeostasis and physiological function in tissues and organs
[43,44]. The disturbance of mTOR signaling leads to the abnormal
accumulation of aggregated and unfolded/misfolded proteins, as de-
monstrated in DS brain [20]. The alteration of autophagy seems to be
related with increased OS, however, this relationship is intricate, and
increasing evidence suggests that the mTOR/autophagy axis plays a
dual role in the cellular response to OS [31]. On one hand, increased
levels of free radicals are involved in the regulation of autophagic
survival signals and death processes and on the other hand, autophagy
provides protection against oxidative damage [4]. Increased mTOR and
reduced autophagy, could lead to the accumulation of ROS and to the
increase of oxidized proteins [45]. Recent studies from our laboratory
reported, in DS post-mortem brain, the early mTOR hyperactivation,
within the brain, coupled with the impairment of its downstream
and upstream pathways, increased amyloid-β load and
Fig. 6. Validation Experiments: im-
munoprecipitation of PP2A (Panel A and B)
and ARG-1. HNE modifications levels de-
tected by immunoprecipitation of PP2A and
ARG-1 (n = 6/group) in Ts65Dn Veh vs Eu
Veh and Ts65Dn InRapa vs Ts65Dn Veh.
Panels A and B show the
Immunoprecipitation blots and graph re-
lative bar graph of HNE-modified PP2A
between Ts65Dn Veh vs Eu Veh comparison
group (A) and Ts65Dn InRapa vs Ts65Dn
Veh comparison group (B). Panels C and D
show the Immunoprecipitation blots and
graph relative bar graph of HNE-modified
ARG-1 between Ts65Dn Veh vs Eu Veh
comparison group (C) and Ts65Dn InRapa
vs Ts65Dn Veh comparison group (D).
Densitometry values shown in the bar graph
are the mean of 6 samples per each group,
normalized on expression, and are given as
percentage of Eu Veh, set as 100%.
Statistical significance was determined
using one–way ANOVA and Student t-test
analysis (*p < 0.05, **p < 0.01,
***p < 0.001).
Fig. 7. PP2A expression levels and ARG-1 enzyme activity. A) Representative
WB showing PP2A protein levels. B) Quantification of panel A showing PP2A
protein levels. C) Quantification of Arginase activity. Densitometry values
shown in the bar graph are the mean of 8 (WB) samples per each group nor-
malized per total load and are given as percentage of Eu Veh, set as 100%. ARG-
1 assay was performed on 8 samples per group and is reported as U/L ± SEM.
Statistical significance was determined using one–way ANOVA and Student t-
test analysis (*p < 0.05, **p < 0.01, ***p < 0.001).
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hyperphosphorylated tau [17]. In addition, we demonstrated that the
same DS cases reported increased oxidative damage to several compo-
nents of autophagy and proteasome systems confirming a close con-
nection between aberrant mTOR/autophagy, altered proteostasis net-
work and increased OS [27,33]. Furthermore, the analysis of mTOR
expression and phosphorylation in the hippocampus of Ts65Dn mice
showed that the alteration of mTOR/autophagy axis could lead to the
observed increase of oxidative damage [16]. Data from hippocampus
[26] and cortex of Ts65Dn compared with Eu Veh confirm the aberrant
mTOR phosphorylation in our DS model, coupled with reduced au-
tophagy induction, increased APP/Aβ levels, increased tau phosphor-
ylation and enhanced levels of lipoxidized proteins, indexed as protein-
bound HNE. The further analysis of protein specific HNE-modification,
by proteomics, revealed the involvement of key components in the
development of neuronal damage in DS mice. Interestingly, the ma-
jority of proteins found to be lipoxidized in Ts65Dn mice compared to
euploids, namely, fructose-bisphosphate aldolase A, succinyl-CoA:3-
ketoacid coenzyme A transferase 1, alpha-internexin and ubiquitin
thioesterase, have been previously identified as oxidatively modified in
the frontal cortex from human DS sample [27,33]. In addition, few of
those proteins, such as PP2A, were found poly-ubiquitinylated in DS
human brain [46]. The overlap between proteomics data collected on
mice and human DS support the strength of the Ts65Dn strain, which
provides a valuable model to study the molecular mechanisms leading
to brain damage and to test the efficacy of neuroprotective drug
therapies [18,47,48].
Within this context, considering that i) oxidative damage impairs
the proteostasis network and induces protein aggregation, which in
turn favors further accumulation of oxidized cellular targets, starting a
chain of harmful events for the neuron; ii) mTOR hyperactivation im-
pairs protein degradative systems leading to accumulation of oxidized
proteins, including HNE-modified; the ability to restore aberrant mTOR
signaling and remove toxic aggregates could be essential to avoid
neurodegeneration and ameliorate cognitive decline in DS [8]. There-
fore, we aimed to treat Ts65Dn mice with InRapa for 3 months to rescue
brain dysfunction. At the end of the treatment, beyond the increase of
cognitive performances, as demonstrated by RAM and NOR tests, we
observed the restoration of mTOR signaling along with increased au-
tophagosome formation, reduced pathological markers (APP/Aβ and p-
Tau) and reduced lipoxidative damage in both hippocampus and frontal
cortex [26]. In particular, our data indicated that mTOR inhibition
might lead to increased autophagosome formation (as suggested by
increased LC3II, Atg7 and Atg12/5) [26,49,50], which is associated
with the reduction of toxic aggregates and misfolded/lipoxidized pro-
teins accumulation. Our results agree with previous studies demon-
strating that rapamycin-induced activation of autophagy is one of the
principal mechanisms by which the reduction of toxic protein ag-
gregates is achieved in the brain of Tg-AD mice [43,44,51–53]. Indeed,
we also supported that rapamycin is able to reduce oxidative damage by
increasing autophagosome formation in SHSY-5Y neuroblastoma cells
[16].
Proteomics data, by showing a reduction of total lipoxidized pro-
teins in Ts65Dn InRapa compared with Eu, support the protective effect
of InRapa towards OS. Moreover, this effect is evident if we consider the
comparison between Ts65Dn Veh and Ts65Dn InRapa, which indicates
that rapamycin led to reduced lipid peroxidation in InRapa Ts65Dn, as
indexed by the number and the identity of HNE-bound proteins, com-
pared with Ts65Dn Veh. Granted the property of rapamycin to reduce
OS in Ts65Dn mice, we focused our attention on the specific targets of
lipoxidation-mediated damage that could contribute to neurodegen-
eration and whose rescue by rapamycin could lead to the amelioration
of brain pathology and to improved cognitive performance. Among
these, we considered of great interest the lipoxidation and subsequent
recovery of ARG-1 and PP2A.
PP2A is one of the most important serine/threonine phosphatases in
mammalian brains. It accounts for as much as 1% of total cellular
proteins in most tissue and cells. As a highly conserved enzyme, it has
ubiquitous distribution and plays important roles in development, cell
growth, and transformation [54,55]. Together with protein phospha-
tase 1 (PP1), PP2A accounts for more than 80% of the total serine/
threonine phosphatase activity in mammalian cells. Tau phosphoryla-
tion levels are largely regulated by PP2A and, to a lesser degree, by PP1,
PP2B and PP5 in the brain [56]. It is conceivable that the down-reg-
ulation of PP2A is partially responsible for the abnormal tau phos-
phorylation in AD and DS brain [57–60]. In vivo, it was shown that
PP2A inhibition induces tau hyperphosphorylation and spatial memory
deficits [61], and these effects are reversed by the addition of acetyl-l-
carnitine [62]. Moreover, PP2A inhibition by okadaic acid in rats leads
to tau phosphorylation and impairment of spatial memory retention
[63]. Interestingly, Specific PP2A inhibition has been also proven to
affect many brain Ser/Thr kinases implicated in tau phosphorylation
since PP2A inhibition can override the inhibition of these key tau ki-
nases [64]. Thus, by deregulating the activity of tau protein kinases,
PP2A dysfunction can promote aberrant stimulation of signaling cas-
cades that contribute to neuronal and synaptic damage in AD and DS
[56]. The regulation of PP2A is very complicated and until now, the
mechanism for PP2A inactivation has not been fully understood [56].
However, among the potential ways of PP2A deregulation its increased
lipoxidation might be responsible of the reduced phosphatase activity
observed in DS.
Previous studies have demonstrated that the oxidation of PP2A lead
to formation of disulfide bond in the catalytic subunit that is sufficient
to inhibit its phosphatase activity [65]. In addition, it has also been
shown that nitration of PP2A affects its function [66].
As reviewed in Di Domenico et al. [7] the increased activity of
several kinases, including DYRK1A and RCAN1, encoded on Chr21, and
GSK3β and CDK5, seems to have a prominent role in tau hyperpho-
sphorylation occurring in the brain of DS mice. In addition, the re-
duction of autophagy, mediated by mTOR hyperactivation, could re-
present a further mechanism that lead to toxic tau deposition by
avoiding its intracellular clearance [13]. In our previous publication
[26], we discussed that the reduction of tau phosphorylation could be
associated with the significantly decreased protein expression of
RCAN1 and DYRK1A and with the improved degradation of hyper-
phosphorylated tau through the induction of autophagy. Our current
data confirm the involvement of aberrantly regulated PP2A among the
mechanism that lead to tau hyperphosphorylation. Ts65Dn mice after
InRapa treatment demonstrate a robust and significant reduction of tau
phosphorylation in the hippocampus and in the frontal cortex of DS
mice. Therefore, here we support the involvement of a further me-
chanism causing tau hyperphosphorylation encompassing the reduced
lipoxidation and the increased expression of PP2A. Our findings are in
agreement with previous results obtained in AD by using memantine;
indeed memantine, as well as rapamycin, was able to restore PP2A
activity and reverse aberrant tau phosphorylation [67].
ARG-1 catalyzes the hydrolysis of L-arginine to urea and ornithine. It
exists primarily in the liver but modest activity has been detected in
extrahepatic tissues like the brain, where it produces ornithine that is
then converted to glutamate and proline. Glutamate acts itself as neu-
rotransmitter or can be converted to γ-amino butyric acid (GABA) [68].
To date, a large body of evidences has shown that synaptic deficits and
memory impairment, in trisomic mouse models of DS, are largely de-
termined by altered GABAergic signaling [69,70]. The Akt-mTOR
pathway is involved in dendrite morphogenesis and synaptic plasticity,
and it has been shown to modulate both glutamatergic and GABAergic
synaptic transmission [71]. Montesinos and coworkers demonstrated
that oral rapamycin treatment resulted in the fully restoration of hip-
pocampal BDNF-LTP and basal synaptic transmission of Ts1Cje mouse
model of DS [72]. Furthermore, many studies suggest that there is a
competition between arginase and nitric oxide synthases (NOS), for L-
arginine and that they control each other's levels [68]. Elevated NO
levels, produced by increased NOS activity, drive nitration of Aβ and
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enhance aggregation and plaque formation [73], suggesting that the
balance between ARG-1 and NOS determines the acceleration vs miti-
gation of amyloid deposition [74]. In addition, the NO-related nitration
of tau has also been observed in different tauopathies [75,76]. A recent
study by Hunt and colleagues [77] showed that overexpression of ARG-
1 in the CNS of Tg4510 tau transgenic mice significantly reduced
phospho-tau species and tangle pathology by decreasing several kinases
capable of phosphorylating tau, decreasing inflammation, and mod-
ulating mTOR activity. Conversely, conditional deletion of ARG-1 in
myeloid cells resulted in increased tau accumulation. Overall these
studies suggest that the lipoxidation of ARG-1 contributes to its reduced
activity thus leading to the development of brain neurodegeneration in
DS by affecting different pathological aspects of the disease. Indeed,
ARG-1 dysfunction might lead to altered synaptic transmission, aber-
rant mTOR activation, Aβ deposition and tau hyperphosphorylation.
The mechanism by which HNE modification impairs ARG-1 activity is
not known. We hypothesize that, similarly to PP2A, critical amino acid
residues in the catalytic domain are oxidatively modified in the pre-
sence of increased levels of HNE. However, InRapa treatment, by re-
ducing ARG-1 protein-bound HNE levels, rescues its enzyme activity
and conceivably contributes to the recovery of the pathway above-
mentioned as previously demonstrated by the increased levels of PSD95
and STX1 [26], and the reduced levels of mTOR phosphorylation, tau
phosphorylation and Aβ deposition.
In conclusions, we previously demonstrated that InRapa treatment
improves cognition in DS mice rescuing molecular pathways associated
with aberrant mTOR phosphorylation. Here we added further pieces to
the puzzle, by showing that the decrease of protein-bound HNE levels,
by rapamycin treatment, is a crucial mechanism leading to reduced
lipoxidative damage in DS mice associated with reduced AD neuro-
pathology (Fig. 8). Considering that mTOR pathway is a central hub at
the crossroad of multiple intracellular signaling, we propose that In-
Rapa treatment is able to modulate lipoxidation and might represent a
valuable therapeutic strategy to reduce the early development of AD
pathology in DS population.
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altered synaptic transmission, aberrant
mTOR activation, Aβ deposition and tau
hyperphosphorylation. On the right panel,
InRapa treatment, by reducing PP2A and
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